In line with these clinical data, experimental NASH in AnxA1-KO mice is characterized by increased liver fibrosis, suggesting that AnxA1 can prevent the fibrogenic evolution of NASH. Here, ANXA1 is linked to metabolic dysfunction-associated steatohepatitis.